High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis

Research output: Contribution to journalArticle

Abstract

Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (anti-CCP) antibodies are related to clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor α (TNFα) inhibitors. Methods: The study was carried out on 132 patients with advanced rheumatoid arthritis refractory to disease-modifying antirheumatic drugs. Patients were treated with infliximab (n = 63), etanercept (n = 35) or adalimumab (n = 34). All patients completed 1 year of follow-up, and 126 were evaluable for clinical response according to the disease activity score (DAS) criteria. IgM, IgA and IgG rheumatoid factors and anti-CCP antibodies were assessed by ELISA both before anti-TNFa treatment and 1 year later. Results: The DAS response was reached in 66% of evaluable patients (61% infliximab, 65% etanercept and 76% adalimumab; p = 0.354). A significant reduction in the rheumatoid factor level was reported by all treatment groups after 1 year. The frequency of positive tests for the different antibodies did not differ between responders and non-responders at baseline; however, significantly higher IgA rheumatoid factor levels were reported by the non-responder group (130.4 U/ml (interquartile range 13.8-276.7) v24.8 U/ml (10.2-90.8); p = 0.003). A significant decrease (p

Original languageEnglish
Pages (from-to)302-307
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume66
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Rheumatoid Factor
Immunoglobulin A
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Antibodies
Antirheumatic Agents
Refractory materials
Immunoglobulin M
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Therapeutics
Adalimumab
Infliximab
cyclic citrullinated peptide
Etanercept

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

@article{18a9111df4c4414b94478cf17d085cdc,
title = "High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis",
abstract = "Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (anti-CCP) antibodies are related to clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor α (TNFα) inhibitors. Methods: The study was carried out on 132 patients with advanced rheumatoid arthritis refractory to disease-modifying antirheumatic drugs. Patients were treated with infliximab (n = 63), etanercept (n = 35) or adalimumab (n = 34). All patients completed 1 year of follow-up, and 126 were evaluable for clinical response according to the disease activity score (DAS) criteria. IgM, IgA and IgG rheumatoid factors and anti-CCP antibodies were assessed by ELISA both before anti-TNFa treatment and 1 year later. Results: The DAS response was reached in 66{\%} of evaluable patients (61{\%} infliximab, 65{\%} etanercept and 76{\%} adalimumab; p = 0.354). A significant reduction in the rheumatoid factor level was reported by all treatment groups after 1 year. The frequency of positive tests for the different antibodies did not differ between responders and non-responders at baseline; however, significantly higher IgA rheumatoid factor levels were reported by the non-responder group (130.4 U/ml (interquartile range 13.8-276.7) v24.8 U/ml (10.2-90.8); p = 0.003). A significant decrease (p",
author = "Francesca Bobbio-Pallavicini and Roberto Caporali and Claudia Alpini and Sfefano Avalle and Epis, {Oscar M.} and Catherine Klersy and Carlomaurizio Montecucco",
year = "2007",
month = "3",
doi = "10.1136/ard.2006.060608",
language = "English",
volume = "66",
pages = "302--307",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis

AU - Bobbio-Pallavicini, Francesca

AU - Caporali, Roberto

AU - Alpini, Claudia

AU - Avalle, Sfefano

AU - Epis, Oscar M.

AU - Klersy, Catherine

AU - Montecucco, Carlomaurizio

PY - 2007/3

Y1 - 2007/3

N2 - Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (anti-CCP) antibodies are related to clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor α (TNFα) inhibitors. Methods: The study was carried out on 132 patients with advanced rheumatoid arthritis refractory to disease-modifying antirheumatic drugs. Patients were treated with infliximab (n = 63), etanercept (n = 35) or adalimumab (n = 34). All patients completed 1 year of follow-up, and 126 were evaluable for clinical response according to the disease activity score (DAS) criteria. IgM, IgA and IgG rheumatoid factors and anti-CCP antibodies were assessed by ELISA both before anti-TNFa treatment and 1 year later. Results: The DAS response was reached in 66% of evaluable patients (61% infliximab, 65% etanercept and 76% adalimumab; p = 0.354). A significant reduction in the rheumatoid factor level was reported by all treatment groups after 1 year. The frequency of positive tests for the different antibodies did not differ between responders and non-responders at baseline; however, significantly higher IgA rheumatoid factor levels were reported by the non-responder group (130.4 U/ml (interquartile range 13.8-276.7) v24.8 U/ml (10.2-90.8); p = 0.003). A significant decrease (p

AB - Objective: To investigate whether rheumatoid factor isotypes and anti-cyclic citrullinated peptide (anti-CCP) antibodies are related to clinical response in patients with rheumatoid arthritis treated with tumour necrosis factor α (TNFα) inhibitors. Methods: The study was carried out on 132 patients with advanced rheumatoid arthritis refractory to disease-modifying antirheumatic drugs. Patients were treated with infliximab (n = 63), etanercept (n = 35) or adalimumab (n = 34). All patients completed 1 year of follow-up, and 126 were evaluable for clinical response according to the disease activity score (DAS) criteria. IgM, IgA and IgG rheumatoid factors and anti-CCP antibodies were assessed by ELISA both before anti-TNFa treatment and 1 year later. Results: The DAS response was reached in 66% of evaluable patients (61% infliximab, 65% etanercept and 76% adalimumab; p = 0.354). A significant reduction in the rheumatoid factor level was reported by all treatment groups after 1 year. The frequency of positive tests for the different antibodies did not differ between responders and non-responders at baseline; however, significantly higher IgA rheumatoid factor levels were reported by the non-responder group (130.4 U/ml (interquartile range 13.8-276.7) v24.8 U/ml (10.2-90.8); p = 0.003). A significant decrease (p

UR - http://www.scopus.com/inward/record.url?scp=34147220774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147220774&partnerID=8YFLogxK

U2 - 10.1136/ard.2006.060608

DO - 10.1136/ard.2006.060608

M3 - Article

C2 - 17079248

AN - SCOPUS:34147220774

VL - 66

SP - 302

EP - 307

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 3

ER -